These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10539585)

  • 1. Towards a reinforced agency role of health insurers in Belgium and The Netherlands.
    Schut FT; van Doorslaer EK
    Health Policy; 1999 Jul; 48(1):47-67. PubMed ID: 10539585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands.
    Lamers LM; van Vliet RC; van de Ven WP
    Health Policy; 2003 Jul; 65(1):49-62. PubMed ID: 12818745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belgium: risk adjustment and financial responsibility in a centralised system.
    Schokkaert E; Van de Voorde C
    Health Policy; 2003 Jul; 65(1):5-19. PubMed ID: 12818742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belgium and The Netherlands revisited.
    van Doorslaer E; Schut FT
    J Health Polit Policy Law; 2000 Oct; 25(5):875-87. PubMed ID: 11068731
    [No Abstract]   [Full Text] [Related]  

  • 5. Market-oriented health care reforms and policy learning in the Netherlands.
    Helderman JK; Schut FT; van der Grinten TE; van de Ven WP
    J Health Polit Policy Law; 2005; 30(1-2):189-209. PubMed ID: 15943393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has solidarity survived? A comparative analysis of the effect of social health insurance reform in four European countries.
    Maarse H; Paulus A
    J Health Polit Policy Law; 2003 Aug; 28(4):585-614. PubMed ID: 12956517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Netherlands: health system review.
    Schäfer W; Kroneman M; Boerma W; van den Berg M; Westert G; Devillé W; van Ginneken E
    Health Syst Transit; 2010; 12(1):v-xxvii, 1-228. PubMed ID: 21132996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demand-side strategies to deal with moral hazard in public insurance for long-term care.
    Bakx P; Chernichovsky D; Paolucci F; Schokkaert E; Trottmann M; Wasem J; Schut F
    J Health Serv Res Policy; 2015 Jul; 20(3):170-6. PubMed ID: 25770020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adjusted capitation: recent experiences in The Netherlands.
    van de Ven WP; van Vliet RC; van Barneveld EM; Lamers LM
    Health Aff (Millwood); 1994; 13(5):120-36. PubMed ID: 7868016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mandatory pooling as a supplement to risk-adjusted capitation payments in a competitive health insurance market.
    Van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    Soc Sci Med; 1998 Jul; 47(2):223-32. PubMed ID: 9720641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managed competition in The Netherlands: lessons from five years of health care reform.
    van de Ven W; Rutten F
    Aust Health Rev; 1995; 18(1):9-27. PubMed ID: 10141966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk sharing as a supplement to imperfect capitation: a tradeoff between selection and efficiency.
    van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    J Health Econ; 2001 Mar; 20(2):147-68. PubMed ID: 11252368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adjusted capitation payments for catastrophic risks based on multi-year prior costs.
    van Barneveld EM; van Vliet RC; van de Ven WP
    Health Policy; 1997 Feb; 39(2):123-35. PubMed ID: 10165042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a capitation formula for competing health insurers. An empirical analysis.
    van Vliet RC; van de Ven WP
    Soc Sci Med; 1992 May; 34(9):1035-48. PubMed ID: 1631603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk adjustment and risk sharing: the Israeli experience.
    Shmueli A; Chernichovsky D; Zmora I
    Health Policy; 2003 Jul; 65(1):37-48. PubMed ID: 12818744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk sharing between competing health plans and sponsors.
    van Barneveld EM; van Vliet RC; van de Ven WP
    Health Aff (Millwood); 2001; 20(3):253-62. PubMed ID: 11585175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a business case for quality in The Netherlands? A critical analysis of the recent reforms of the health care system.
    Custers T; Arah OA; Klazinga NS
    Health Policy; 2007 Jul; 82(2):226-39. PubMed ID: 17070956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of healthcare reform in the Netherlands.
    Rutten F
    Pharmacoeconomics; 2004; 22(2 Suppl 2):65-71. PubMed ID: 15660478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial sustainability versus access and quality in a challenged health system: an examination of the capitation policy debate in Ghana.
    Atuoye KN; Vercillo S; Antabe R; Galaa SZ; Luginaah I
    Health Policy Plan; 2016 Nov; 31(9):1240-9. PubMed ID: 27178747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managed competition in the Netherlands: Do insurers have incentives to steer on quality?
    Stolper KCF; Boonen LHHM; Schut FT; Varkevisser M
    Health Policy; 2019 Mar; 123(3):293-299. PubMed ID: 30268584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.